Efficacy and safety of rucaparib in previously treated, locally advanced or metastatic urothelial carcinoma from a phase 2, open-label trial (ATLAS).

ATLAS evaluated the efficacy and safety of the PARP inhibitor rucaparib in patients with previously treated locally advanced/unresectable or metastatic urothelial carcinoma (UC). Patients with UC were enrolled independent of tumor homologous recombination deficiency (HRD) status and received rucaparib 600 mg BID.

Flexible Fiber Optic vs Digital Ureteroscopy and Enhanced vs Unenhanced imaging for Diagnostic and Treatment of Upper Tract Urothelial Carcinoma: Results from the Clinical Research Office of the Endourology Society (CROES)-UTUC Registry.

To compare the oncological outcomes of patients with upper tract urothelial carcinoma (UTUC) undergoing kidney-sparing surgery (KSS) with fiber-optic (FO) vs digital (D) ureteroscopy (URS). To evaluate the oncological impact of image enhance technologies such as narrow-band imaging (NBI) and Image 1S in patients with UTUC.

X